Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
This is not a financial advice!
Recent block buy
Upcoming catalyst end of March 2024
Low float of 44.47M
Short float 11.20%
Keep an eye on 2.80 level - needs to get broken for a further upmove.
SL under 1.8
Potenential gap fill: TP approx. 14 -15
Most info on the chart.
Trade carefully!
This is not a financial advice!
Recent block buy
Upcoming catalyst end of March 2024
Low float of 44.47M
Short float 11.20%
Keep an eye on 2.80 level - needs to get broken for a further upmove.
SL under 1.8
Potenential gap fill: TP approx. 14 -15
Most info on the chart.
Trade carefully!
Note
uhh it's getting hotTrade closed: target reached
booom what a trade!
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.